ClinicalTrials.gg
RecruitingNCT06732089Updated Dec 13, 2024

Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study

An observational study in Major Depressive Disorder (MDD), Major Depressive Episode and Treatment-Resistant Major Depressive Disorder, sponsored by Unity Health Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Unity Health Toronto · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Depressive Disorder, Major by Unity Health Toronto — 8 open to participants now, 9 under way, none of them phase 3. Depressive Disorder, Major · Unity Health Toronto.

Started
2024
with 2 others
Observational
6 of 17
3 open now
Registered
15th of 17
by date

Among the 17 studies in Depressive Disorder, Major by Unity Health Toronto, this one is one of 3 that started in 2024, is one of 6 observational ones, and was the 15th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

8 of the 17 studies in Depressive Disorder, Major by Unity Health Toronto are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Depressive Disorder, Major by Unity Health Toronto, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about remote mental health monitoring technology for adults with treatment-resistant depression. The main question it aims to answer is: are digital mental health monitoring tools (an electronic data capture platform and wearable device (e.g., smartwatch or smart-ring)) feasible to implement alongside clinical treatment for depression? The secondary aim of this study is to inform preliminary clinical parameters for larger, definitive studies.

Participants receiving neuropsychiatric treatment (repetitive transcranial magnetic stimulation, intravenous ketamine, or electroconvulsive therapy) as part of their regular medical care for treatment-resistant depression in the Interventional Psychiatry Program will have their clinical assessment data entered into a digital platform and will wear an accessory-based wearable device for the duration of treatment.

Read the detailed description

This observational study with retrospective data analysis is conducted in patients with treatment-resistant depression (TRD) undergoing neuropsychiatric clinical treatment (rTMS, IVK, or ECT) in the Interventional Psychiatry Program (IPP) at St. Michael's Hospital. Participants will have scores from a self-report assessment of anxiety (GAD-7) and a self-report (PHQ-9) or clinician-administered (MADRS) assessment of depression completed as part of clinical care entered into the Research Electronic Database Capture (REDCap) web-based platform after each treatment session. This will facilitate retrospective analysis of mental health symptom change and treatment response over the course of treatment. Participants will also have the opportunity to wear an accessory-based wearable device (e.g., smartwatch or ring) throughout the course of treatment to passively capture physiological biometrics of physical and mental health (e.g., heart rate, temperature, sleep, activity). This two-year pilot study aims to recruit a total of 200 participants with TRD to retrospectively assess the feasibility and efficacy of integrating remote health sensing and monitoring platforms in psychiatric clinical care.

03

Conditions studied

  • Major Depressive Disorder (MDD)
  • Major Depressive Episode
  • Treatment-Resistant Major Depressive Disorder

Keywords

  • pilot study
  • digital health monitoring
  • wearable device
  • remote measurement-based care
  • treatment-resistant depression
  • observational study
  • feasibility study
  • electronic data capture
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults suffering from treatment-resistant depression (TRD) who are being treated in the Interventional Psychiatry Program at St. Michael's Hospital, Unity Health Toronto. Patients have a confirmed diagnosis of Major Depressive Disorder (MDD) and are experiencing a Major Depressive Episode (MDE) at the time of enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (aged 18+) who are capable of giving
  • Patients meeting diagnostic criteria for major depressive disorder (MDD) without psychotic symptoms according to the
  • Currently experiencing a major depressive episode (MDE)
  • Montgomery-Asperg Depression Rating Scale (MADRS) score greater than 20 at screening
  • Patients meeting criteria for treatment-resistant depression (TRD): failure of 2 or more adequate trials of antidepressant therapy of adequate dose and duration during the current episode
  • Enrollment in one of the treatment modalities (rTMS, IVK, or ECT) at the Interventional Psychiatry Program at St. Michael's Hospital, Unity Health Toronto
  • Ownership of a smartphone (for participants using wearable devices)

Exclusion criteria

Exclusion Criteria:

  • Individuals without Internet access (required to access study platforms)
  • Medication changes, aside from the treatment received through the IPP, one month (28 days) before screening, or during the entire duration of treatment (variable based on treatment arm)
  • Participants who do not speak English fluently enough to successfully communicate study information, answer questions accurately, and/or obtain
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • rTMS

    Participants in this group are enrolled to recieve rTMS treatment as part of their clinical care in the Interventional Psychiatry Program.

  • IVK

    Participants in this group are enrolled to receive intravenous ketamine (IVK) treatment as part of their clinical care in the Interventional Psychiatry Program.

  • ECT

    Participants in this group are enrolled to receive electroconvulsive therapy (ECT) as part of their clinical care in the Interventional Psychiatry Program.

06

What researchers measure

Primary outcomes

  1. Feasibility

    To determine the feasibility of using a web-based digital platform and wearable devices to collect active and passive data, respectively, among adults receiving clinical treatment for treatment-resistant depression. This will be measured by: number of recruitments (minimum threshold of 6-7 participants/month), recruitment rates (relative to invited patient-participants; minimum threshold of 80%), dropout rates (maximum threshold of 30%), reasons for dropout (qualitative), and data completion/adherence rates (minimum threshold of 70%).

    Time frame: From Screening and Baseline Visit (Day 0) to last treatment day (approximately 2-8 weeks depending on treatment group)

Secondary outcomes

  1. Longitudinal Changes in Symptom Presentation

    To quantify changes in active (clinical symptoms) and passive (physiological) measures of physical (activity) and mental health (depression, anxiety, sleep) over time. Active data will focus on anxiety and depression symptoms across treatment, as reported on the GAD-7, PHQ-9, and MADRS. Passive data will focus on physiological biometrics (e.g., heart rate, respiration, step count, metabolic equivalency, body temperature, sleep staging, skin conductance response) captured by the wearable devices.

    Time frame: From Screening and Baseline Visit (Day 0) to last treatment day (approximately 2-8 weeks depending on treatment group)

  2. Predicting Treatment Response, Remission, and Relapse

    To model and predict the likelihood of a patient achieving anxiety/depression treatment response (reduction greater than or equal to 50% on clinical assessment), remission (assessment score less than clinical threshold), and relapse (assessment score greater than clinical threshold after achieving remission) captured through active self-/clinician-administered assessments, based on longitudinal active and passive data.

    Time frame: From Screening and Baseline Visit (Day 0) to last treatment day (approximately 2-8 weeks depending on treatment group)

  3. Personalized Digital Phenotype Profiling (pDPP)

    To construct pDPPs (a.k.a. digital fingerprints) for each participant based on longitudinal active and passive data. This will be achieved using machine learning (ML), artificial intelligence (AI), and advanced data analytic principles.

    Time frame: From Screening and Baseline Visit (Day 0) to last treatment day (approximately 2-8 weeks depending on treatment group)

07

Study locations

1 of 1 sites recruiting
  • St. Michael's Hospital, Unity Health Toronto
    Toronto, Ontario M5B 1W8, Canada
    Recruiting
    • Dr. Venkat Bhat, M.D., F.R.C.P.C. · Contactvenkat.bhat@unityhealth.to · 416-360-4000
    • Dr. Karisa Parkington, Ph.D. · Contactkarisa.parkington@unityhealth.to · 416-360-4000
    • Dr. Reinhard Janssen Aguilar, M.D. · Contact
    • Dr. Alice Rueda, Ph.D. · Contact
    • Gyu Hee Lee, B.Sc. · Contact
    • Fathima Adamsahib, B.Sc., P.A.-C. · Contact
    • Dr. Perry Menzies, M.D., F.R.C.P.C. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Oct 2026, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 13, 2024
StartEst.
Dec 16, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732089
Collaborators
University of Toronto, Toronto Metropolitan University
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Dec 16, 2024 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 13, 2024

Study contacts

Dr. Venkat Bhat, M.D., F.R.C.P.C.
Contact
venkat.bhat@unityhealth.to
416-360-4000 ext. 76404
Dr. Karisa Parkington, Ph.D.
Contact
karisa.parkington@unityhealth.to
416-360-4000 ext. 76228
Dr. Srihar Krishnan, Ph.D., Peng., F.C.A.E.
study chair · Toronto Metropolitan University
Dr. Wendy Lou, Ph.D.
study chair · Dalla Lana School of Public Health, University of Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion